title: Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes.
abstract: We have examined several variables inherent in aerosolizing cationic lipid:DNA complexes using a jet nebulizer and thereby have optimized the delivery of functional complexes. Maximal aerosol transfer efficiency of cationic lipid:pDNA complexes was quantitated and shown to require the presence of at least 25 mM NaCL as an excipient. This is possibly related to effects on the measured zeta potentials of the complex, which indicate that the complexes are more highly charged in solutions of physiological ionic strength than in solutions of low ionic strength. Inclusion of saline also resulted in retention of the starting lipid to plasmid DNA (pDNA) ratio following nebulization. These data were used to design in vitro aerosolization experiments with tissue culture cells that resulted in the identification of a cationic lipid:pDNA ratio of 0.75:1 (mol:mol) as being optimal for aerosolization. This formulation largely protected pDNA from shear degradation during nebulization and produced a respirable aerosol droplet size (1-3 microns). It was tested further in a mouse model and shown to result in the dose-dependent transfection of mouse lungs, generating the equivalent of several picograms of reporter gene activity per mouse lung. The results of these experiments have provided a set of optimal conditions for nebulizing cationic lipid:pDNA complexes that can be used as a starting point for the further evaluation of aerosol delivery of these nonviral gene delivery vectors in vivo.
authors.affiliation: Genzyme Corporation, Framingham, MA 0701-9322, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Eastman
authors.forename: J D
authors.initials: JD
authors.lastname: Tousignant
authors.forename: M J
authors.initials: MJ
authors.lastname: Lukason
authors.forename: H
authors.initials: H
authors.lastname: Murray
authors.forename: C S
authors.initials: CS
authors.lastname: Siegel
authors.forename: P
authors.initials: P
authors.lastname: Constantino
authors.forename: D J
authors.initials: DJ
authors.lastname: Harris
authors.forename: S H
authors.initials: SH
authors.lastname: Cheng
authors.forename: R K
authors.initials: RK
authors.lastname: Scheule
mesh_terms: D000281:Administration, Intranasal; D000336:Aerosols; D000818:Animals; D002412:Cations / Q000008:administration & dosage*; D004247:DNA / Q000008:administration & dosage*; D004337:Drug Carriers; D005260:Female; D008055:Lipids / Q000008:administration & dosage*; D008081:Liposomes; D008168:Lung / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009330:Nebulizers and Vaporizers; D009994:Osmolar Concentration; D010316:Particle Size; D010957:Plasmids; D014162:Transfection
chemical_list: D000336:Aerosols; D002412:Cations; D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D004247:DNA